Search

Comments regarding the Agency’s goals behind the proposed quality metrics program.

We are supportive of the International Pharmaceutical Excipient Council of The Americas' recommendations detailed in their correspondence that USP remove references to dietary supplements and their ingredients.

CHPA supports EPA's efforts to streamline regulations under RCRA. CHPA has two central comments on the proposal.

On behalf of the Consumer Healthcare Products Association, enclosed herein are comments on the 2019 revised draft guidance document as well as FDA’s decision to revoke CPG 400.400.

The reason we’re here today is to discuss a provision of the Affordable Care Act that requires holders of tax‐preferred healthcare accounts to seek a prescription if they wish to use those accounts to purchase an OTC medicine. We believe this requirement is bad policy for both the American consumer and the U.S. healthcare system.

CHPA appreciates the opportunity to provide comments on the FDA’s draft guidance for industry entitled “Best Practices in Developing Proprietary Names for Drugs”. CHPA members hope the Agency will find the suggested revisions in these comments informative as the final version of the guidance is developed.

In principle, CHPA supports an early approval program for proposed proprietary drug names. However, should FDA decide to implement a program, we expect that FDA would publish a draft Guidance for Industry and we would provide further comment based on the criteria.

CHPA appreciates the opportunity to provide information on features to add and potential functionality improvements to make the Dietary Supplement Label Database a more useful tool for regulators, consumers, and other users of the database.

CHPA appreciates the opportunity to provide information relevant to use of the term “natural” in food labeling, and believes that a formal definition will help to reduce consumer confusion and provide clarity to manufacturers and marketers making claims relying upon such a definition.